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The aim of this study was to determine the effect of HNSCC tumour treatment on systemic Th1 and Th2
cytokine levels and investigate correlations with clinicopathological parameters. IL2, IL4, IL5, IL6, IL8,
IL10, IL13, GMCSF, IFNg and TNFa were measured in the serum of 101 newly-presenting HNSCC
patients (9 oral cavity, 27 oropharynx, 57 laryngopharynx, 1 sinonasal, 1 parotid and 6 unknown), prior
to and following treatment, using a Quantibodys array based multiplex sandwich ELISA (Raybiotech).
Data were analysed with respect to T stage, nodal status, age and sex of the patient as well as time
between collection of pre- and post-treatment serum. A signiﬁcant decrease in the levels of the Th2
cytokines IL4, IL5, IL6 and IL10 and the Th1 cytokines IL2 and IL8 was observed between the pre- and
post-treatment serum samples. IL13 and TNFa were signiﬁcantly higher in early stage (T1/T2) tumours
compared with late stage (T3/T4) and this trend was maintained for nodal involvement. IL4 was higher
in node positive patients compared with node negative, whereas the converse was true for IL2; IL4 was
also higher in younger patients compared with the older age group. These results suggest that removal
of HNSCC tumours from patients results in reduced circulating Th2 cytokines without a concurrent
increase in Th1 cytokines, indicative of a partial rebalance of the Th1/Th2 system following treatment.
Furthermore the cytokine proﬁle may be inﬂuenced by the size and nodal involvement of the tumour.
& 2011 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Head and neck cancer is the sixth most common solid tumour
in the western world accounting for approximately 5% of all
cancer incidences globally. Head and neck encompasses a number
of distinct subsites and thus should not be considered a single
disease entity. About 90% of head and neck tumours arise from
cells of the squamous epithelium lining the oral cavity, larynx,
nasopharynx, oropharynx and hypopharynx, forming the sub-
group of head and neck squamous cell carcinomas (HNSCC).
The incidence of head and neck cancers is more frequent in
males compared with females and although recent reports indi-
cate a better prognosis for patients with human papillomavirus
(HPV) positive oropharyngeal tumour [1], those patients with
HPV negative tumours still have a 5 year survival rate of less than
50%, despite advances in surgical, chemo- and radiotherapeutic
treatment strategies.
Immune suppression in cancer patients is well recognised,
particularly in patients with HNSCC [2,3], where suppression can
include changes in the levels of immunoregulatory cytokines [4,5]ospital, Hull HU16 5JQ, UK.
Y-NC-ND license.and the balance of key immune cells including natural killer cells,
dendritic cells, cytotoxic T cells, T-regulatory cells and T helper
cells [6–8].
T helper cells play a key role in controlling the immune
response and can be subdivided into T-helper 1 (Th1) and
T-helper 2 (Th2)-like cells, deﬁned by the cytokine repertoire
they produce and subsequent responses. Th1-like cells are prin-
cipally involved in promoting cell-mediated immunity, and gen-
erally are considered as the host’s main anti-cancer mechanism,
whereas Th2-like cells stimulate an antibody-mediated response,
principally targeting extracellular pathogens [9]. The Th1 and Th2
responses are normally reciprocally balanced but a shift towards a
Th2-like response has been observed in cancer patients, including
those with HNSCC, by measuring serum cytokines [10–12].
Previous reports have investigated cytokines in serum from
HNSCC patients with a view to identifying biomarkers or prognostic
indicators [13,14]. The current study has employed a multiplex
cytokine array to establish the levels of ten different cytokines,
involved in the control of the Th1/Th2 response, simultaneously in a
large cohort (n¼101) of newly-presenting HNSCC patients both pre-
and post-treatment. This has established the effect of removing the
tumour, a possible cytokine source, on the systemic levels of these
cytokines. The large cohort of patients has also enabled sub-site
speciﬁc differences to be determined. The results provide a better
understanding of the regulatory pathways involved in tumour
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anti-tumour therapies.2. Materials and methods
2.1. Patients
Subsequent to ethical approval (South Humber local research
ethics committee; LREC-05/Q1105/55) patients with newly-
presenting HNSCC were recruited (n¼101). Exclusion criteria
included previous diagnosis and treatment for any other form of
cancer, active autoimmune or co-existing infectious disease and
previous radio- or chemotherapy. Tumour samples included 9 oral
cavities (anterior tongue, ﬂoor of mouth, palate, lip), 27 orophar-
ynx (tongue base, tonsil), 57 laryngopharynx (larynx, hypophar-
ynx), 1 sinonasal, 1 parotid and 6 unknown sub-sites (Table 1).
2.2. Serum separation
Following written informed consent venous blood was col-
lected into two 7 ml serum separator vacutainers (SSTTM II, BD
Biosciences, Oxford, UK), both prior to and after allocated treat-
ment (between 0.5 and 16 months post-surgery, radio- and/or
chemotherapy). The blood was clotted for 30 min at 4 1C before
centrifugation (400g for 10 min) and the resulting upper layer of
serum was aliquoted and stored at 80 1C prior to cytokine
determination.
2.3. Serum cytokine determination
Serum from 101 paired pre- and post-treatment samples stored at
80 1C were thawed and used in the Quantibodys Human Th1/Th2
Array 1 (Raybiotech Inc, Tebu-bio, Cambs, UK) as directed by the
manufacturer. Brieﬂy, the kit consisted of a glass slide with 16 wells,
spotted in quadruplicate with capture antibodies directed against 10
human cytokines (IL2, IL4, IL5, IL6, IL8, IL10, IL13, GMCSF, IFNg and
TNFa). Following air drying, each well was incubated with serial
dilutions of the provided cytokine standard (IL2, IL4, IL5, IFNg, TNFa,
2–1600 pg/ml; IL6, IL8, IL10, IL13, GMCSF, 1–800 pg/ml) or sample,
overnight at 4 1C. Cytokines were evaluated in pre- and post-treat-
ment serum samples on the same array, on the same day, tominimise
intra-sample variation. Following stringent washes with supplied
buffers, detection antibody was added to each well for 1 h at room
temperature and Cy3-equivalent dye-conjugated streptavidin was
added for another hour at room temperature to detect bound
cytokine. Excess ﬂuorophore was washed off and the slide dried by
centrifugation (150g for 3 min).Table 1
Clinicopathological features of HNSCC patients.
Tumour site n Age Sex T stage Node status
Median (range) F M T1/T2 T3/T4 N0 Nþ
Laryngopharynx 57 65 (41–92) 5 52 25 32 34 23
Oropharynx 27 57 (30–67) 4 23 16 10a 5 22
Oral cavity 9 59 (53–69) 3 6 6 3 3 6
Naso/sinonasal 1 57 0 1 0 1 1 0
Parotid 1 85 0 1 1 0 1 0
Unknown 6 b 1b 3 c b 4
Total 101 – 13 86 48 46 44 55
a One oropharynx was of unknown T stage.
b Two unknown primary tumours were of unknown age, sex and nodal status.
c All of the unknown primary tumours were of unknown T stage.The signal intensity for each spot was determined using an
Axon GenePix laser scanner equipped with Cy3 wavelength
detection (555 nm excitation, 565 nm emission) and cytokine
concentrations were determined using Q analyser software
v8.10.4. The software automatically removed outliers and gener-
ated standard curves; both linear and log regression curves were
generated and the curve, which gave the best regression line
(r2 closest to 1), was used to determine sample concentrations.
2.4. Statistical analysis
The results were analysed using SPSS version 18 (SPSS Inc,
Chicago, USA). Cytokine levels and detection were analysed as
continuous and dichotomous variables, respectively. Missing data
were excluded from each analysis and non-parametric tests were
used as appropriate where the data were not normally distributed.
Differences between pre- and post-treatment serum cytokine
levels or detectability were determined using the Wilcoxon’s signed
rank sum test for related samples and the Fisher’s exact test,
respectively. Associations between cytokine levels or detectability
and tumour sub-site or time between pre- and post-treatment
sample collection were determined using the Kruskal–Wallis one
way ANOVA for unrelated samples and the Fisher’s exact test,
respectively. Relationships between cytokine levels or detectability
with T stage (early T1/T2; late T3/T4), nodal status (N0, Nþ), sex or
age were determined using the Mann Whitney U test for unrelated
samples and the Fisher’s exact test, respectively. The laryngopharynx
group was the only one with a sufﬁcient number to investigate
separately for relationships with clinicopathological parameters.3. Results
3.1. Patient demographics
Newly-presenting patients with HNSCC (n¼101) were recruited
in the study between August 2008 and November 2010. The most
abundant subtypes of HNSCC tumour were the laryngopharynx
group (n¼57) and the oropharynx tumours (n¼27; Table 1). For
all tumour sub-sites there was a greater incidence in males. There
was a relatively even distribution of both early (T1/T2) and late
(T3/T4) stage tumours at all sub-sites, however, there was signiﬁ-
cantly less nodal involvement in the laryngopharynx group com-
pared with other tumour sites (p¼0.001). The median age of the
whole group of HNSCC patients was 62 (range 30–92), with the
laryngopharynx group containing signiﬁcantly more patients over
the age of 60 (p¼0.004), data not shown.
3.2. Effect of treatment on cytokine expression
Of the ten cytokines investigated IL2, IL5, IL8, IL13 and TNFa
were detected in less than 50% of the pre- and post-treatment
serum samples; IL4 was also detected in less than 50% of the post-
treatment samples. There were no signiﬁcant differences in the
number of samples having detectable levels for any of the
cytokines between the pre and post-treatment samples. In con-
trast although the median levels of IL2, IL4, IL5, IL6, IL8 and IL10
were zero, the Wilcoxon signed rank test showed signiﬁcantly
higher cytokine levels in pre-treatment as compared with post-
treatment samples (Table 2).
3.3. Relationship of cytokine expression with patient
clinicopathology and demographics
Following grouping of tumour samples into 3 sub-sites: oral
cavity, oropharynx and laryngopharynx, excluding the sinonasal,
Table 2
Median concentrations of cytokines in serum from HNSCC patients pre- and post-treatment.
Cytokine Pre-treatment Post-treatment P value
n Detectable/n total Median (IQR) (pg/ml) n Detectable/n total Median (IQR) (pg/ml)
IL2 44/101 0 (0–7.1) 37/101 0 (0–4.2) 0.02a
IL4 52/101 1.8 (0–7.4) 41/101 0 (0–6.3) 0.04a
IL5 48/101 0 (0–11.1) 42/101 0 (0–6.3) 0.03a
IL6 72/101 2.1 (0–6.6) 65/101 1.9 (0–3.5) 0.01a
IL8 37/101 0 (0–0.7) 31/101 0 (0–0.3) 0.02a
IL10 95/101 15.6 (8.4–40.9) 92/101 15 (5.9–30.9) 0.001a
IL13 46/101 0 (0–3.4) 45/101 0 (0–2.6) 0.26
GM-CSF 64/101 1.7 (0–7.5) 61/101 1.5 (0–4.7) 0.07
IFNc 82/96b 33.5 (10.1–77.9) 80/96b 28.8 (8.6–123.7) 0.59
TNFa 43/91b 0 (0–8.0) 44/91b 0 (0–6.0) 0.90
IQR¼Interquartile range.
a Signiﬁcant P value from Wilcoxon signed rank sum test for related samples.
b Serum samples where levels of IFNg (n¼5), and TNFa (n¼10) were unable to be determined due to the quality of the standard curve.
Fig. 1. Bar chart showing the number of patients with non-detectable/detectable
levels of IL5 in pre-treatment serum samples in relation to the subsite of the
tumour. *po0.05 Fishers exact test.
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no signiﬁcant differences were determined in the levels of any of
the cytokines between the sub-groups. The only signiﬁcant
difference observed was that pre-treatment IL5 was signiﬁcantly
less detectable in laryngopharynx compared with oral cavity or
oropharynx (Fig. 1).
Of the tumour cohort one oropharynx and 6 samples of unknown
primary site had an undeﬁned T stage. The remaining 94 samples
were grouped into early (n¼48) or late (n¼46) stage tumours and
IL13 and TNFa had both signiﬁcantly higher levels and were more
detectable in both pre- and post-treatment serum from the early stage
tumour group compared with the late stage group, with the difference
beingmost apparent for TNFa (Table 3). The higher levels observed for
IL2 and IL5 in both pre- and post-treatment serum samples from
patients with early stage tumours compared with the late stage
samples also approached signiﬁcance and IL5 was signiﬁcantly more
detectable in early stage tumours but only in the pre-treatment
samples (Table 3). Analysing laryngopharynx samples on their own
maintained the signiﬁcance for IL13 and TNFa and the difference for
IL2 level with T stage became signiﬁcant (data not shown).
The results of the cytokine levels relating to T stage were
mirrored to a certain extent when they were considered in relation
to the nodal status of the patient, in that levels of both IL13 and
TNFa in serum from patients both pre- and post-treatment were
higher in node negative compared with node positive patients
(Table 4; 2 patients were of unknown nodal status). However,
although the difference in levels for the IL13 pre-treatment samples
and the TNFa post-treatment samples approached signiﬁcance only
the IL13 levels in the post-treatment samples were signiﬁcantly
higher in node negative patients. Levels of IL2 were also signiﬁcantly
higher in the pre-treatment serum from node negative patientscompared with those in serum from node positive patients whereas
the converse was true for IL4 in pre-treatment serum. The results for
the levels of the cytokines in relation to nodal status of the tumour
were also reﬂected in the detectability of these cytokines (Table 4).
When the laryngopharynx group was considered separately the
parameters mentioned above, which approached signiﬁcance in
relation to nodal status, became signiﬁcant, as did the higher level
of IL5 in both the pre- and post-treatment serum samples of the
node negative group compared with the node positive group
(p¼0.04 and 0.03; data not shown).
Signiﬁcantly more patients presenting HNSCC were male (n¼86)
compared with female (n¼13; unknown n¼2), however the only
differences observed in the levels of cytokines with respect to the
sex of the patient were that IL2, IL5 and IL13 were all detected at
signiﬁcantly higher levels in females compared with males (p¼0.03,
0.01 and 0.01, respectively) but there was no signiﬁcant difference
in the numbers of samples having detectable levels of cytokines in
relation to gender (data not shown).
Samples were divided into two age groups: those from patients
r60 (n¼46) and those from patients 460 (n¼53; unknown
n¼2), and it was determined that levels of IL4 in both pre- and
post-treatment serum samples were signiﬁcantly higher in the
younger patients compared with the older group as were the levels
of IL8 in the post-treatment serum samples (p¼0.03, 0.01 and
0.02). There were also signiﬁcantly more samples with detectable
levels of IL4 in the post-treatment samples from the younger
patient group (data not shown).
3.4. Effect of time of post-treatment sample collection on
serum cytokines
The post-treatment collection sample was taken after patients
had completed all their treatment (surgery, radio- and che-
motherapy), however the time between pre- and post-treatment
samples varied between 0.5 and 16 months. The samples were
therefore divided into three groups: 0.5–3 months (n¼23), 4–6
months (n¼51) and 7–16 months (n¼27) between collections.
However, apart from the fact that the IL2 level was higher and
more detectable in the 4–6 months group and the IL8 level was
higher and more detectable in the 0.5–3 months group, the time
of collection of the post-treatment sample had no signiﬁcant
inﬂuence on the cytokine level or detectability.
4. Discussion
The problem with many studies of head and neck cancer to
date is that they have used mixed cohorts of patients, which are
Table 3
Median concentrations pg/ml (IQR) of cytokines in serum from HNSCC patients both pre- and post-treatment in relation to T stage of the tumour.
Cytokine n Detectable/n total Early stage (T1/2) n Detectable/n total Late stage (T3/4) P value
IL2 pre 26/48 2.1 (0–13.7) 16/46 0 (0–5.7) 0.06
IL2 post 22/48 0 (0–8.3) 14/46 0 (0–1.9) 0.06
IL4 pre 25/48 2.0 (0–6.8) 23/46 0.8 (0–6.5) 0.88
IL4 post 18/48 0 (0–3.1) 19/46 0 (0–6.6) 0.71
IL5 pre 28/48b 4.4 (0–17.0) 17/46b 0 (0–7.9) 0.07
IL5 post 24/48 0.3 (0–7.5) 14/46 0 (0–4.9) 0.06
IL6 pre 35/48 2.7 (0–6.9) 31/46 1.8 (0–6.5) 0.55
IL6 post 32/48 1.9 (0–6.6) 27/46 1.9 (0–3.1) 0.26
IL8 pre 17/48 0 (0–0.7) 18/46 0 (0–0.9) 0.86
IL8 post 16/48 0 (0–1.0) 15/46 0 (0–0.3) 0.60
IL10 pre 47/48 16.4 (9.6–37.4) 42/46 15.3 (6.2–50.1) 0.58
IL10 post 45/48 17 (7.0–32.7) 41/46 12.7 (5.1–30.1) 0.43
IL13 pre 30/48b 1.1 (0–6.2) 14/46b 0 (0–0.8) 0.002a
IL13 post 27/48b 0.6 (0–5.6) 15/46b 0 (0–0.6) 0.006a
GM-CSF pre 34/48 2.2 (0–7.7) 26/46 0.9 (0–7.6) 0.39
GMCSF post 31/48 1.8 (0–4.1) 27/46 1.6 (0–5.4) 0.87
IFNc pre 40/47c 35 (10.5–77.7) 36/42c 28.2 (10.6–96.3) 0.98
IFNc post 42/47c 39.9 (13.7–109.5) 32/42c 21.5 (3.2–144.8) 0.47
TNFa pre 27/45bc 2.5 (0–13.3) 13/39c,b 0 (0–2.4) 0.009a
TNFa post 27/45b,c 3.5 (0–12.6) 12/39c,b 0 (0–2.7) 0.003a
a Signiﬁcant P value from Mann–Whitney U test for unrelated samples.
b Signiﬁcant difference in detectability po0.05 Fisher’s exact test.
c Serum samples where levels of IFNg, and TNFa were unable to be determined due to the quality of the standard curve.
Table 4
Median concentrations pg/ml (IQR) of cytokines in serum from HNSCC patients both pre- and post-treatment in relation to nodal status of the patient.
Cytokine n Detectable/n total N0 n Detectable/n total Nþ P value
IL2 pre 25/44b 2.9 (0–13.7) 19/55b 0 (0–5.5) 0.03a
IL2 post 19/44 0 (0–6.5) 18/55 0 (0–2.0) 0.16
IL4 pre 17/44b 0 (0–3.3) 33/55b 2.7 (0–10.9) 0.04a
IL4 post 14/44 0 (0–2.0) 25/55 0 (0–8.8) 0.11
IL5 pre 22/44 0.8 (0–30.3) 26/55 0 (0–8.8) 0.37
IL5 post 20/44 0 (0–9.1) 21/55 0 (0–5.4) 0.23
IL6 pre 30/44 1.9 (0–9.4) 40/55 2.6 (0–5.1) 0.89
IL6 post 24/44 1.4 (0–3.2) 39/55 2.1 (0–3.7) 0.25
IL8 pre 16/44 0 (0–0.7) 19/55 0 (0–0.7) 0.84
IL8 post 10/44 0 (0–0) 21/55 0 (0–0.5) 0.15
IL10 pre 40/44 11.3 (7.1–31.3) 53/55 18.4 (9.6–41.5) 0.12
IL10 post 40/44 12.4 (4.7–27.3) 50/55 17.1 (7.1–32.0) 0.20
IL13 pre 25/44 0.8 (0–5.6) 21/55 0 (0–1.9) 0.06
IL13 post 25/44b 0.8 (0–5.6) 19/55b 0 (0–0.7) 0.005a
GM-CSF pre 25/44 1.4 (0–6.8) 37/55 2.1 (0–8.1) 0.52
GMCSF post 26/44 1.4 (0–4.3) 34/55 1.8 (0–4.9) 0.86
IFNc pre 36/43c 28.5 (4.4–66.4) 44/51c 37.8 (12.2–79.8) 0.46
IFNc post 38/43c 28.4 (8.4–93.8) 40/51c 26.4 (8.9–153.5) 0.78
TNFa pre 22/41c 2.4 (0–12.7) 20/48c 0 (0–4.5) 0.13
TNFa post 22/41c 3.4 (0–12.6) 20/48c 0 (0–4.8) 0.08
a Signiﬁcant P value from Mann–Whitney U test for unrelated samples.
b Signiﬁcant difference in detectability po0.05 Fisher’s exact test.
c Serum samples where levels of IFNg, and TNFa were unable to be determined due to the quality of the standard curve.
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current study describes a large cohort of newly-presenting HNSCC
patients from which data for individual subgroups has been
obtained and is, to our knowledge, the largest study of multiplex
cytokine analysis in HNSCC patients pre- and post-treatment to
date. The advantage of the Quantibodys array over conventional
ELISA methodology is that, the level of multiple cytokines can be
detected simultaneously in a small volume of serum, saving time
and generating a picture of cytokine interactions.
Some systemic cytokines in cancer patients may arise from the
tumour itself, skewing the immune response towards Th2 pro-
moting evasion of host anti-tumour mechanisms [15–18]. The
current study supports this since the levels of the Th2 cytokines
IL4, IL5, IL6 and IL10 were all found to decrease signiﬁcantly
following tumour excision. However, the tumour may inﬂuenceperipheral blood mononuclear cells from HNSCC patients, which
can have elevated Th2 cytokines and suppressed Th1 cytokines
compared with those from controls shifting to Th1 post-opera-
tively [19,10].
In contrast to Jebreel et al. who found a decrease in Th1 (IL12)
and an increase in Th2 (IL10) cytokines in HNSCC patients (n¼57)
compared with controls (n¼40) [5], the decrease in Th2 cytokines
observed in the current study was not accompanied by an
increase in the levels of the Th1 cytokines, in fact IL2 and IL8
also signiﬁcantly decreased following treatment. This agrees with
Lathers et al. who found that HNSCC patients (n¼101) had
increased levels of the Th2 cytokines IL4, IL6 and IL10 compared
with healthy controls (n¼40), but that the Th1 cytokines IL2 and
GMCSF were also increased [17]. Hoffmann et al. also found
elevated levels of the pro-inﬂammatory cytokines IL6 and IL8 in
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[20] and Gu¨naydin et al. found that IL10 was signiﬁcantly more
detectable in patients with laryngeal carcinoma (n¼50) than
controls (n¼15) [21], however, neither Hoffman nor Lathers
looked at treatment or sub-sites effects.
Sub-site discrimination is important because the survival and
recurrence rates of patients with tumours from distinct sub-sites
of the head and neck differ, although the reasons are controversial
[22]—it may depend on a combination of the anatomical location,
i.e. being more visible (oral cavity) or causing functional impair-
ment (larynx), leading to earlier diagnosis or molecular differ-
ences [23]. The current study was unable to identify differences in
cytokine levels between sub-sites, the only difference observed
was the lower frequency of detection of IL5 in the laryngopharynx
patients compared with the other sub-sites, the signiﬁcance of
which is unknown. This is in contrast to earlier studies, which
showed that patients with tumours of the oral cavity had less
detectable IL10 [5,18]. The current results would suggest the
physical location of the tumour rather than the Th1/Th2 balance
inﬂuences the prognosis of HNSCC patients [24].
Both IL13 and TNFa were higher in pre- and post-treatment
serum from patients with early stage tumours compared with that
from late stage patients and concurrently higher, although not
always signiﬁcantly so, in patients with node negative tumours
compared with node positive tumours, suggesting their association
with smaller more localised tumours, particularly in the laryngo-
pharynx group. This is consistent with the role of TNFa as a Th1-like
cytokine having anti-tumour effects targeting tumour vasculature.
However, TNFa is also involved in cachexia in cancer patients [25]
and has been found associated with advanced stage breast tumours
with nodal involvement but this difference could be due to site
variations [26]. IL13 is a Th2 cytokine negatively inﬂuencing anti-
tumour immunity and can be an autocrine growth factor for some
cancer cells [27,28], therefore may have been expected to be
elevated in patients with late stage, more aggressive, HNSCC
tumours. IL13 however is less likely to be involved in peripheral
immune evasion as it cannot act directly on T cells unlike IL4 [27],
which was detected at higher levels in the pre-treatment serum
from patients with node positive tumours where it may be involved
in immune evasion allowing the tumour to spread. In contrast the
Th1 cytokine IL2 was higher in the pre-treatment serum of patients
with node negative tumours where it may promote anti-tumour
responses limiting the spread of the tumour. Sparano et al. also
found that the Th2 cytokine IL10 was greater in HNSCC patients
(n¼58) with nodal involvement and T3/T4 stage tumours whereas
the Th1 cytokine IL12 was greater in patients without nodal
involvement and with T1/T2 stage tumours [4]. Gu¨naydin et al. also
found that IL10 was more detectable in patients with advanced
stage laryngeal tumours with nodal involvement, however out of
50 patients investigated, there were only 10 with detectable IL10
levels [21].
Younger patients with HNSCC tend to have a poorer prognosis
than their older counterparts [29] and in the current study it was
found that the Th2 cytokine IL4 was higher in both the pre- and
post-treatment serum from younger patients, which ﬁts with the
theory that the Th2 cytokines have a negative impact on the
immune environment inﬂuencing patient prognosis.
The post-treatment samples in the current study were col-
lected when the patients had completed all of their treatments,
however, due to differences in the regimen this varied between
0.5 and 16 months after the pre-treatment sample, but this had
little inﬂuence on the cytokine levels.
In conclusion, treatment of HNSCC reduces the levels of certain
Th2-like cytokines however, an inverse Th1 gain is not observed and
some cytokines are associated with the size and nodal involvement
of the tumour. In addition to those in the periphery, cytokines in themicroenvironment of the tumour should also be considered and are
currently being investigated by our group along with other immu-
nological parameters to gain a clearer picture of the overall immune
responses occurring in these patients. Survival data are also being
accumulated under the current ethical approval, to determine the
relationship of these parameters with patient prognosis.Acknowledgements
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